China: CDE Rejected 542 Drug Applications Last Year
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China Meheco Group Co., Ltd. operates as a pharmaceutical company in China and internationally. The company imports and exports China national medicines and health products; and produces and distributes pharmaceutical and health care products; and operates retail chain pharmacies. Its products include bulk pharmaceutical chemicals antibiotic fermentation and chemical synthesis tablets, injections, and capsules; antibiotics; medicines for the treatment of cardio-cerebrovascular diseases, chronic diseases, and diabetes; antiviral drugs; anti-infectious agents; gastrointestinal drugs; non-steroidal anti-inflammatory drugs; anti-allergic agents; specialty botanicals; western medicine preparations; Chinese patent medicines and herbal pieces; medical equipment and supplies; biological products and raw materials; chemical raw materials; chemical and natural medicines; and nutrition products. The company also plants, processes, warehouses, and transports ginseng, licorice, ephedra, rhubarb, fennel, and other herbs. China Meheco Group Co., Ltd. was founded in 1984 and is based in Beijing, China.
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021:…
A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR…
Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up…
China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential…
Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR…
Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
See our Cookie Privacy Policy Here
